Zydus Cadila and Germany's Pieris have signed an agreement to co-develop and market drugs based on the anticalin protein molecule. The India-based drug maker is to have marketing rights for the drugs in India and other emerging markets, Pieris in leading developed markets. First off the mark is expected to be their PRS-110, a targeted drug for a range of cancer tumors. (Click here for more
)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?